Core Insights - AVITA Medical reported a commercial revenue of $17.1 million for Q3 2025, a 13% decrease from $19.5 million in Q3 2024, primarily due to reimbursement challenges [6][10] - The company expects full-year revenue for 2025 to be between $70 million and $74 million, down from previous guidance of $76 million to $81 million [16] - AVITA Medical's cash management improved, with net cash use decreasing to $6.2 million in Q3 from $10.1 million in Q2 2025 [9][15] Financial Results - Commercial revenue for Q3 2025 was $17.1 million, a decrease of $2.5 million or 13% compared to the same period in 2024 [6][10] - Operating expenses decreased by 24% to $23.0 million, down from $30.2 million in Q3 2024, reflecting cost management strategies [12][9] - Net loss improved to $13.2 million, or $0.46 per share, compared to a net loss of $16.2 million, or $0.62 per share, in Q3 2024 [14] Other Quarterly Milestones - The company is focusing on approximately 200 key U.S. burn and trauma centers, targeting an addressable market of roughly $1.3 billion [3][8] - AVITA Medical received CE Mark approval for RECELL GO® in September, allowing for commercialization in Europe, starting with Germany, Italy, and the UK [5] - The reimbursement environment for RECELL has normalized, with all seven Medicare Administrative Contractors confirming payment rates [4] Clinical and Regulatory Milestones - RECELL demonstrated its effectiveness in achieving wound closure with less donor skin and faster healing, supported by data from over 8,000 patients [7] - Real-world data indicated a 36% reduction in hospital stay length and approximately $42,000 in cost savings per patient compared to traditional methods for treating second-degree burns [7] Portfolio Execution - AVITA Medical's strategy focuses on an integrated portfolio of RECELL, Cohealyx, and PermeaDerm, aiming for disciplined growth in the acute wound care market [8] - The company currently serves about 5% of the $1.3 billion addressable market, indicating significant growth potential [8]

Financial Performance & Outlook - Second quarter commercial revenue reached $18.4 million, a 21% increase compared to Q2 2024[8] - A backlog in unpaid provider claims impacted RECELL performance, resulting in an estimated $10 million reduction in RECELL revenue[14] and a ~20% drop in demand[13] - Full-year 2025 revenue guidance revised from $100 million - $106 million to $76 million - $81 million, reflecting a growth of ~19% to 27% compared to FY2024[38] - The company now anticipates cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026[38] - Net loss decreased by 35.7%, and operating expenses decreased by 9.1%[37] Product Impact & Clinical Data - RECELL treatment achieves a significant 36% reduction in hospital Length of Stay (LOS) for patients with deep second-degree burns <30% total body surface area[11, 17] - Cohealyx enables autograft readiness in five to ten days, offering a faster path to healing for full-thickness wounds[11, 24] Market Expansion & Strategy - The U S Total Addressable Market (TAM) for burn and trauma with multi-product strategy is estimated at $3.5 billion[33] - Two major hospitals are expanding RECELL use to burns <20% TBSA, potentially adding ~150 additional patients per month[29] - VAC submissions are now active in ~25% of the ~130 U S burn centers[30]

Core Insights - AVITA Medical, Inc. will host its inaugural Acute Wound Care Showcase 2025 on May 13, 2025, via webcast [1] - The event will feature presentations from key executives and provide an overview of the company's approach to acute wound care [2][3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery [4] - The RECELL® System is a key product, approved by the FDA for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - The company also markets Cohealyx™, a collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix, in the U.S. [4] Product Portfolio - The Acute Wound Care Showcase will highlight the company's product portfolio, including RECELL®, Cohealyx™, and PermeaDerm® [2] - The RECELL System is approved for various applications internationally, including burns and full-thickness skin defects, with regulatory approvals in Australia, Europe, and Japan [5] Event Details - The event will include testimonials from physicians and patients, showcasing the clinical and economic benefits of AVITA's technologies [3] - A live Q&A session will conclude the event, allowing for direct engagement with attendees [3]